Our technology platform allows for the rapid and flexible engineering of:
- Oncolytic Viruses
- Invasive and non-invasive Bacteria
- Proteins and protein complexes
Redbiotec has a successful track record having developed and produced over 100 novel constructs since foundation of the company in 2006.
With our technology we are an active driver of the industry towards more complex and bigger therapeutics.
Proven commercial and scientific track record
Among other projects Redbiotec has proven its leadership in giving several pharma companies access to a complex key antigen in the field of CMV. In 2014 this led to the acquisition of our spin-off company Redvax by Pfizer Inc.